(12) **Translation of European patent specification**

(11) **NO/EP 2280732 B1**

(19) NO

NORWAY

(51) Int Cl.
A61K 39/395 (2006.01)
A61P 9/00 (2006.01)
A61P 11/00 (2006.01)
A61P 19/00 (2006.01)
C07K 16/00 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.02.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.10.17
(86)	European Application Nr.	09739607.1
(86)	European Filing Date	2009.04.28
(87)	The European Application's Publication Date	2011.02.09
(30)	Priority	2008.04.28, US, 48522
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
	Designated Extension States:	AL BA RS
(73)	Proprietor	Humanigen, Inc., 533 Airport Boulevard Suite 400, Burlingame, CA 94010, USA
(72)	Inventor	BEBBINGTON, Christopher, R., 132 Avila Road, San Mateo, CA 94402, USA LUEHRSEN, Kenneth, 556 Noel Ct, Santa Barbara, CA 93111, USA YARRANTON, Geoffrey, T., 1148 Balboa Ave., Burlingame, CA 94010, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR**

(56) References Cited:

WO-A2-03/068920, TOMLINSON I M ET AL: "The Structural repertoire of the human Vk domain", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 18, 1 January 1995 (1995-01-01), pages 4628-4638, XP002974449, ISSN: 0261-4189, SCHROEDER H W ET AL: "PREFERENTIAL UTILIZATION OF CONSERVED IMMUNOGLOBULIN HEAVY CHAIN VARIABLE GENE SEGMENTS DURING HUMAN FETAL LIFE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 87, no. 16, 1 August 1990 (1990-08-01), pages 6146-6150, XP002689791, ISSN: 0027-8424, DOI: 10.1073/PNAS.87.16.6146, WO-A2-2006/111353, WO-A2-2007/092939, SCHOONBROODT ET AL.: 'Oligonucleotide-assisted cleavage and ligation: a novel directional DNA cloning technology to capture cDNAs. Application in the construction of a human immune antibody phage-display library.' NUCLEIC ACIDS RES. vol. 33, no. 9, 2005, pages 1 - 14, E81, XP002581479, WO-A2-2006/122797, US-A1- 2008 095 767, KHEE HWANG W Y ET AL: "Use of human germline genes in a CDR homology-based approach to antibody humanization",

METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 35-42, XP027216561, ISSN: 1046-2023 [retrieved on 2005-04-19], N Tuaillon ET AL: "Biased utilization of DHQ52 and JH4 gene segments in a human Ig transgenic minilocus is independent of antigenic selection", The Journal of Immunology, 15 March 1994 (1994-03-15), page 2912, XP055347467, UNITED STATES Retrieved from the Internet: URL:http://www.jimmunol.org/content/jimmunol/152/6/2912.full.pdf, WO-A2-2006/055778, US-A1- 2004 053 365, US-A1- 2006 228 358, KRINNER E M ET AL: "A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 5, 1 February 2007 (2007-02-01), pages 916-925, XP005663412, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2006.03.020 [retrieved on 2006-05-11], ALMAGRO JUAN C ET AL: "Humanization of antibodies", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 13, 1 January 2008 (2008-01-01), pages 1619-1633, XP009126790, ISSN: 1093-9946

Patentkrav

1. Anti-GM-CSF-antistoff, omfattende:

(a) en V_H-region som omfatter aminosyresekvensen til SEQ ID NO: 5; og

(b) en V_L-region som omfatter aminosyresekvensen til SEQ ID NO: 7.

2. Anti-GM-CSF_antistoff ifølge krav 1, hvor antistoffet er et IgG.

3. Anti-GM-CSF-antistoff ifølge krav 1 eller 2, hvor antistoffet omfatter en tungkjede-konstant region med aminosyresekvensen angitt i SEQ ID NO: 11 og en kappa lettkjede-konstant region med aminosyresekvensen angitt i SEQ ID NO: 10.

4. Farmasøytisk sammensetning omfattende et anti-GM-CSF-antistoff ifølge et hvilket som helst av kravene 1 til 3.

5. Anti-GM-CSF-antistoff ifølge et hvilket som helst av kravene 1 til 3 for anvendelse som et medikament.

6. Anti-GM-CSF-antistoff ifølge et hvilket som helst av kravene 1 til 3 for anvendelse i behandling av en pasient med en kronisk inflammatorisk sykdom.

7. Anti-GM-CSF-antistoff ifølge et hvilket som helst av kravene 1 til 3 for anvendelse i behandling av en pasient med osteopeni, reumatoid artritt, astma, multippel sklerose, psoriasis, kronisk obstruktiv lungesykdom, idiopatisk trombocytopenisk purpura, hjertesvikt, hjerteskader grunnet en iskemisk hendelse, eller diabetes.